Cargando…
Transdermal Drug Delivery Systems and Their Use in Obesity Treatment
Transdermal drug delivery (TDD) has recently emerged as an effective alternative to oral and injection administration because of its less invasiveness, low rejection rate, and excellent ease of administration. TDD has made an important contribution to medical practice such as diabetes, hemorrhoids,...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8657870/ https://www.ncbi.nlm.nih.gov/pubmed/34884558 http://dx.doi.org/10.3390/ijms222312754 |
_version_ | 1784612600027283456 |
---|---|
author | Li, Zhiguo Fang, Xuexun Yu, Dahai |
author_facet | Li, Zhiguo Fang, Xuexun Yu, Dahai |
author_sort | Li, Zhiguo |
collection | PubMed |
description | Transdermal drug delivery (TDD) has recently emerged as an effective alternative to oral and injection administration because of its less invasiveness, low rejection rate, and excellent ease of administration. TDD has made an important contribution to medical practice such as diabetes, hemorrhoids, arthritis, migraine, and schizophrenia treatment, but has yet to fully achieve its potential in the treatment of obesity. Obesity has reached epidemic proportions globally and posed a significant threat to human health. Various approaches, including oral and injection administration have widely been used in clinical setting for obesity treatment. However, these traditional options remain ineffective and inconvenient, and carry risks of adverse effects. Therefore, alternative and advanced drug delivery strategies with higher efficacy and less toxicity such as TDD are urgently required for obesity treatment. This review summarizes current TDD technology, and the main anti-obesity drug delivery system. This review also provides insights into various anti-obesity drugs under study with a focus on the recent developments of TDD system for enhanced anti-obesity drug delivery. Although most of presented studies stay in animal stage, the application of TDD in anti-obesity drugs would have a significant impact on bringing safe and effective therapies to obese patients in the future. |
format | Online Article Text |
id | pubmed-8657870 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-86578702021-12-10 Transdermal Drug Delivery Systems and Their Use in Obesity Treatment Li, Zhiguo Fang, Xuexun Yu, Dahai Int J Mol Sci Review Transdermal drug delivery (TDD) has recently emerged as an effective alternative to oral and injection administration because of its less invasiveness, low rejection rate, and excellent ease of administration. TDD has made an important contribution to medical practice such as diabetes, hemorrhoids, arthritis, migraine, and schizophrenia treatment, but has yet to fully achieve its potential in the treatment of obesity. Obesity has reached epidemic proportions globally and posed a significant threat to human health. Various approaches, including oral and injection administration have widely been used in clinical setting for obesity treatment. However, these traditional options remain ineffective and inconvenient, and carry risks of adverse effects. Therefore, alternative and advanced drug delivery strategies with higher efficacy and less toxicity such as TDD are urgently required for obesity treatment. This review summarizes current TDD technology, and the main anti-obesity drug delivery system. This review also provides insights into various anti-obesity drugs under study with a focus on the recent developments of TDD system for enhanced anti-obesity drug delivery. Although most of presented studies stay in animal stage, the application of TDD in anti-obesity drugs would have a significant impact on bringing safe and effective therapies to obese patients in the future. MDPI 2021-11-25 /pmc/articles/PMC8657870/ /pubmed/34884558 http://dx.doi.org/10.3390/ijms222312754 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Li, Zhiguo Fang, Xuexun Yu, Dahai Transdermal Drug Delivery Systems and Their Use in Obesity Treatment |
title | Transdermal Drug Delivery Systems and Their Use in Obesity Treatment |
title_full | Transdermal Drug Delivery Systems and Their Use in Obesity Treatment |
title_fullStr | Transdermal Drug Delivery Systems and Their Use in Obesity Treatment |
title_full_unstemmed | Transdermal Drug Delivery Systems and Their Use in Obesity Treatment |
title_short | Transdermal Drug Delivery Systems and Their Use in Obesity Treatment |
title_sort | transdermal drug delivery systems and their use in obesity treatment |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8657870/ https://www.ncbi.nlm.nih.gov/pubmed/34884558 http://dx.doi.org/10.3390/ijms222312754 |
work_keys_str_mv | AT lizhiguo transdermaldrugdeliverysystemsandtheiruseinobesitytreatment AT fangxuexun transdermaldrugdeliverysystemsandtheiruseinobesitytreatment AT yudahai transdermaldrugdeliverysystemsandtheiruseinobesitytreatment |